Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

SB 1676Session 2025

Diabetes Management

S 1676 Filed

Underlined text would be added to current law. Struck-through text would be removed.

Florida Senate - 2025 SB 1676 By Senator Smith 17-00656C-25 20251676__ 1 A bill to be entitled 2 An act relating to diabetes management; creating s. 3 385.2035, F.S.; requiring the Department of Health to 4 create and maintain a website; specifying requirements 5 for such website; requiring federally qualified health 6 centers or covered entities to make a good faith 7 effort to schedule appointments within a specified 8 timeline; authorizing the department to adopt rules; 9 amending s. 465.0275, F.S.; defining terms; 10 authorizing a pharmacist to prescribe and dispense a 11 30-day supply of insulin drugs, glucagon drugs, 12 diabetes devices, and diabetic ketoacidosis devices 13 under certain circumstances; prohibiting a pharmacist 14 from requiring patients to pay more than a certain 15 amount for such drugs and devices; requiring 16 pharmacists to provide a specified website address to 17 certain patients; providing construction; requiring 18 the department to provide a certain notice to all 19 pharmacists; creating ss. 627.64081, 627.65746, and 20 641.31078, F.S.; defining terms; requiring health 21 insurance policies and health maintenance contracts, 22 respectively, to provide coverage for laboratory and 23 diagnostic testing and screening for diabetes under 24 certain circumstances; prohibiting health insurance 25 policy and health maintenance contracts from exposing 26 certain cost-sharing requirements; providing 27 applicability; amending s. 893.055, F.S.; requiring a 28 dispenser to report to the electronic health 29 recordkeeping system certain drugs and devices 30 dispensed; defining terms; providing an effective 31 date. 32 33 Be It Enacted by the Legislature of the State of Florida: 34 35 Section 1. Section 385.2035, Florida Statutes, is created 36 to read: 37 385.2035 Website for persons referred to a federally 38 qualified health center.— 39 (1) The Department of Health shall create and maintain a 40 website to collect information from, and provide information to, 41 persons who may benefit from referrals to a federally qualified 42 health center, including persons who were provided the website 43 address under s. 465.0275(3)(d). The website must, at a minimum, 44 do all of the following: 45 (a) Allow persons to submit their name, address, age, 46 contact details, income, race, diabetes diagnosis status, and 47 prescribed outpatient diabetes medications. 48 (b) Enable the department to do all of the following: 49 1. Determine whether the listed medications are covered 50 outpatient drugs available at a reduced cost through a federally 51 qualified health center or another covered entity. 52 2. Provide persons with the name, address, and phone number 53 of relevant federally qualified health centers or other covered 54 entities and general information about health care services 55 available at these centers, including how to access primary 56 care. 57 3. Share a person’s name, contact details, and referral 58 status with the recommended federally qualified health center or 59 covered entity. 60 (2) Each federally qualified health center or covered 61 entity that receives a person’s name, contact information, and 62 referral from the Department of Health must make a good faith 63 effort to schedule an appointment for that person within 30 days 64 after receiving the information. 65 (3) The Department of Health may adopt rules to implement 66 this section. 67 Section 2. Subsection (3) is added to section 465.0275, 68 Florida Statutes, to read: 69 465.0275 Emergency prescription refill.— 70 (3)(a) As used in this subsection, the term: 71 1. “Diabetes device” means a device, including, but not 72 limited to, a blood glucose test strip, a glucometer, a 73 continuous glucometer, a lancet, a lancing device, or an insulin 74 syringe, used to cure, diagnose, mitigate, prevent, or treat 75 diabetes or low blood sugar. 76 2. “Diabetic ketoacidosis device” means a device used to 77 screen for or prevent diabetic ketoacidosis. 78 3. “Glucagon drug” means a drug that contains glucagon 79 which is prescribed for self-administration on an outpatient 80 basis and approved by the federal Food and Drug Administration 81 to treat low blood sugar. 82 4. “Insulin drug” means a drug, including, but not limited 83 to, an insulin pen, which contains insulin and is prescribed for 84 self-administration on an outpatient basis and approved by the 85 federal Food and Drug Administration to treat diabetes. 86 (b) Notwithstanding subsections (1) and (2), if a patient 87 informs a pharmacist that he or she has less than a 7-day supply 88 of any insulin drug, glucagon drug, diabetes device, or diabetic 89 ketoacidosis device, the pharmacist may immediately prescribe 90 and dispense up to a 30-day supply of such drugs or devices if 91 all of the following conditions are met: 92 1. In the pharmacist’s professional judgment, the patient 93 is likely to suffer significant physical harm within 7 days if 94 the drugs or devices are not obtained. 95 2.a. The pharmacist has reviewed the prescription drug 96 monitoring program pursuant to s. 893.055 and determined that no 97 pharmacist has prescribed the drugs or devices to the patient 98 within the past 12 months; 99 b. The pharmacist has contacted the pharmacy that filled 100 the patient’s most recent prescription for the drugs or devices 101 and has confirmed that that no pharmacist has prescribed the 102 drugs or devices to the patient within the past 12 months; or 103 c. The electronic prescription drug monitoring program is 104 unavailable. 105 3. No later than 72 hours after the pharmacist dispenses 106 the drugs or devices, the pharmacist or the pharmacist’s 107 representative provides notice to the practitioner who, other 108 than the pharmacist, most recently prescribed the drugs or 109 devices to the patient. 110 4. The patient pays for, or has health insurance coverage 111 for, the drugs or devices. 112 (c) A pharmacist who prescribes and dispenses the drugs and 113 devices as described under this subsection may not require the 114 patient to pay more than the amount the coinsurance, copayment, 115 deductible, or other out-of-pocket expense that the patient’s 116 health insurance coverage imposes or, if the patient does not 117 have health insurance, the usual customary charge for the drugs 118 or devices. 119 (d) If a patient requests drugs or devices under this 120 subsection and the pharmacist determines that the patient does 121 not have health insurance coverage for the drugs or devices or 122 the patient informs the pharmacist that the patient is concerned 123 that the net cost to the patient for such supply of the drugs or 124 devices is unaffordable, the pharmacist must provide such 125 patient the Department of Health’s website address as specified 126 in s. 385.2035. 127 (e) This subsection may not be construed to prohibit a 128 pharmacist from requiring a patient to submit to the pharmacist, 129 before the pharmacist prescribes or dispenses a supply of the 130 drugs or devices, proof of health insurance coverage for the 131 patient, personal identification for the patient, contact 132 information for a health care provider providing treatment to 133 the patient, information concerning previous prescriptions 134 issued to the patient for the insulin drug, glucagon drug, 135 diabetes devices or diabetic ketoacidosis device, a sworn 136 statement by the patient stating that the patient is unable to 137 timely obtain the insulin drug, glucagon drug, diabetes device, 138 or diabetic ketoacidosis device that the patient is seeking 139 pursuant to this subsection without suffering significant 140 physical harm, and any amount required by the pharmacist under 141 paragraph (b). 142 (f) No later than October 1, 2025, the department must 143 provide notice to all pharmacists regarding the requirements of 144 this section. 145 Section 3. Section 627.64081, Florida Statutes, is created 146 to read: 147 627.64081 Coverage for diabetes drugs and devices.— 148 (1) As used in this section, the term: 149 (a) “Cost-sharing requirement” means an insured’s 150 deductible, coinsurance, copayment, or similar out-of-pocket 151 expense. 152 (b) “Diabetes device” means a device, including, but not 153 limited to, a blood glucose test strip, a glucometer, a 154 continuous glucometer, a lancet, a lancing device, or an insulin 155 syringe, used to cure, diagnose, mitigate, prevent, or treat 156 diabetes or low blood sugar. 157 (c) “Diabetic ketoacidosis device” means a device that is 158 used to screen for or prevent diabetic ketoacidosis. 159 (d) “Glucagon drug” means a drug that contains glucagon 160 which is prescribed for self-administration on an outpatient 161 basis and approved by the federal Food and Drug Administration 162 to treat low blood sugar. 163 (e) “Insulin drug” means a drug, including, but not limited 164 to, an insulin pen, which contains insulin and is prescribed for 165 self-administration on an outpatient basis and approved by the 166 federal Food and Drug Administration to treat diabetes. 167 (f) “Laboratory and diagnostic testing and screening for 168 diabetes” includes hemoglobin A1C testing and retinopathy 169 screening. 170 (g) “Noninsulin drug” means a drug, including, but not 171 limited to, a glucagon drug, glucose tablet or glucose gel, that 172 does not contain insulin and is approved by the federal Food and 173 Drug Administration to treat diabetes. 174 (2) A health insurance policy must provide coverage for 175 laboratory and diagnostic testing and screening for diabetes if 176 such testing and screening is covered under the policy, subject 177 to the same policy provisions that apply to other covered 178 services. 179 (3) A health insurance policy may not impose a cost-sharing 180 requirement that exceeds $35 for a 30-day supply of an insulin, 181 noninsulin, or glucagon drug or $100 for a 30-day supply of all 182 medically necessary covered diabetes and diabetic ketoacidosis 183 devices. 184 (4) This section applies to all health insurance policies 185 delivered, issued, renewed, or amended on or after January 1, 186 2026. 187 Section 4. Section 627.65746, Florida Statutes, is created 188 to read: 189 627.65746 Coverage for diabetes drugs and devices.— 190 (1) As used in this section, the term: 191 (a) “Cost-sharing requirement” means an insured’s 192 deductible, coinsurance, copayment, or similar out-of-pocket 193 expense. 194 (b) “Diabetes device” means a device, including, but not 195 limited to, a blood glucose test strip, a glucometer, a 196 continuous glucometer, a lancet, a lancing device, or an insulin 197 syringe, used to cure, diagnose, mitigate, prevent, or treat 198 diabetes or low blood sugar. 199 (c) “Diabetic ketoacidosis device” means a device that is 200 used to screen for or prevent diabetic ketoacidosis. 201 (d) “Glucagon drug” means a drug that contains glucagon 202 which is prescribed for self-administration on an outpatient 203 basis and approved by the federal Food and Drug Administration 204 to treat low blood sugar. 205 (e) “Insulin drug” means a drug, including, but not limited 206 to, an insulin pen, which contains insulin and is prescribed for 207 self-administration on an outpatient basis and approved by the 208 federal Food and Drug Administration to treat diabetes. 209 (f) “Laboratory and diagnostic testing and screening for 210 diabetes” includes hemoglobin A1C testing and retinopathy 211 screening. 212 (g) “Noninsulin drug” means a drug, including, but not 213 limited to, a glucagon drug, glucose tablet, or glucose gel, 214 that does not contain insulin and is approved by the federal 215 Food and Drug Administration to treat diabetes. 216 (2) A health insurance policy must provide coverage for 217 laboratory and diagnostic testing and screening for diabetes if 218 such testing and screening is covered under the policy, subject 219 to the same policy provisions that apply to other covered 220 services. 221 (3) A health insurance policy may not impose a cost-sharing 222 requirement that exceeds $35 for a 30-day supply of an insulin, 223 noninsulin, or glucagon drug or $100 for a 30-day supply of all 224 medically necessary covered diabetes and diabetic ketoacidosis 225 devices. 226 (4) This section applies to all health insurance policies 227 delivered, issued, renewed, or amended on or after January 1, 228 2026. 229 Section 5. Section 641.31078, Florida Statutes, is created 230 to read: 231 641.31078 Coverage for diabetes drugs and devices.— 232 (1) As used in this section, the term: 233 (a) “Cost-sharing requirement” means an insured’s 234 deductible, coinsurance, copayment, or similar out-of-pocket 235 expense. 236 (b) “Diabetes device” means a device, including, but not 237 limited to, a blood glucose test strip, a glucometer, a 238 continuous glucometer, a lancet, a lancing device, or an insulin 239 syringe, used to cure, diagnose, mitigate, prevent, or treat 240 diabetes or low blood sugar. 241 (c) “Diabetic ketoacidosis device” means a device that is 242 used to screen for or prevent diabetic ketoacidosis. 243 (d) “Glucagon drug” means a drug that contains glucagon 244 which is prescribed for self-administration on an outpatient 245 basis and approved by the federal Food and Drug Administration 246 to treat low blood sugar. 247 (e) “Insulin drug” means a drug, including, but not limited 248 to, an insulin pen, which contains insulin and is prescribed for 249 self-administration on an outpatient basis and approved by the 250 federal Food and Drug Administration to treat diabetes. 251 (f) “Laboratory and diagnostic testing and screening for 252 diabetes” includes hemoglobin A1C testing and retinopathy 253 screening. 254 (g) “Noninsulin drug” means a drug, including, but not 255 limited to, a glucagon drug, glucose tablet, or glucose gel, 256 that does not contain insulin and is approved by the federal 257 Food and Drug Administration to treat diabetes. 258 (2) A health maintenance contract must provide coverage for 259 laboratory and diagnostic testing and screening for diabetes if 260 such testing and screening is covered under the policy, subject 261 to the same policy provisions that apply to other covered 262 services. 263 (3) A health maintenance contract may not impose a cost 264 sharing requirement that exceeds $35 for a 30-day supply of an 265 insulin, noninsulin, or glucagon drug or $100 for a 30-day 266 supply of all medically necessary covered diabetes and diabetic 267 ketoacidosis devices. 268 (4) This section applies to all health maintenance contract 269 delivered, issued, renewed, or amended on or after January 1, 270 2026. 271 Section 6. Present subsection (16) of section 893.055, 272 Florida Statutes, is redesignated as subsection (17), a new 273 subsection (16) is added to that section, and paragraph (c) of 274 subsection (4) of that section is amended, to read: 275 893.055 Prescription drug monitoring program.— 276 (4) The following persons must be provided direct access to 277 information in the system: 278 (c) The program manager or designated program and support 279 staff to administer the system. 280 1. In order to calculate performance measures pursuant to 281 subsection (14), the program manager or program and support 282 staff members who have been directed by the program manager to 283 calculate performance measures may have direct access to 284 information that contains no identifying information of any 285 patient, physician, health care practitioner, prescriber, or 286 dispenser. 287 2. The program manager or designated program and support 288 staff must provide the department, upon request, data that does 289 not contain patient, physician, health care practitioner, 290 prescriber, or dispenser identifying information for public 291 health care and safety initiatives purposes. 292 3. The program manager, upon determining a pattern 293 consistent with the department’s rules established under 294 subsection (17) (16), may provide relevant information to the 295 prescriber and dispenser. 296 4. The program manager, upon determining a pattern 297 consistent with the rules established under subsection (17) (16) 298 and having cause to believe a violation of s. 893.13(7)(a)8., 299 (8)(a), or (8)(b) has occurred, may provide relevant information 300 to the applicable law enforcement agency. 301 302 The program manager and designated program and support staff 303 must complete a level II background screening. 304 (16) In the manner prescribed for controlled substances 305 provided under this section, each dispenser shall report to the 306 system all insulin drugs, glucagon drugs, diabetes devices, and 307 diabetic ketoacidosis devices dispensed. The terms “insulin 308 drug,” “glucagon drug,” “diabetes device,” and “diabetic 309 ketoacidosis device” have the same meaning as in s. 310 465.0275(3)(a). 311 Section 7. This act shall take effect July 1, 2025.

Official text from the Florida Legislature. Formatting has been adapted for reading on Ratifi.